Journal
MARINE DRUGS
Volume 20, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/md20080515
Keywords
sclareolide; labdane; hypertension; vasorelaxant activity; Ca(V)1; 2 channels; K(Ca)1; 1 channels; Langendorff perfused heart; docking simulations; molecular dynamics simulations
Categories
Ask authors/readers for more resources
The labdane scaffold presents a valuable starting point for the development of new vasorelaxant agents. The study reveals the regulatory effects of labdane-type compounds on ion channels and provides a molecular basis for their activity.
Sesquiterpenes such as leucodin and the labdane-type diterpene manool are natural compounds endowed with remarkably in vitro vasorelaxant and in vivo hypotensive activities. Given their structural similarity with the sesquiterpene lactone (+)-sclareolide, this molecule was selected as a scaffold to develop novel vasoactive agents. Functional, electrophysiology, and molecular dynamics studies were performed. The opening of the five-member lactone ring in the (+)-sclareolide provided a series of labdane-based small molecules, promoting a significant in vitro vasorelaxant effect. Electrophysiology data identified 7 as a Ca(V)1.2 channel blocker and a K(Ca)1.1 channel stimulator. These activities were also confirmed in the intact vascular tissue. The significant antagonism caused by the Ca(V)1.2 channel agonist Bay K 8644 suggested that 7 might interact with the dihydropyridine binding site. Docking and molecular dynamic simulations provided the molecular basis of the Ca(V)1.2 channel blockade and K(Ca)1.1 channel stimulation produced by 7. Finally, 7 reduced coronary perfusion pressure and heart rate, while prolonging conduction and refractoriness of the atrioventricular node, likely because of its Ca2+ antagonism. Taken together, these data indicate that the labdane scaffold represents a valuable starting point for the development of new vasorelaxant agents endowed with negative chronotropic properties and targeting key pathways involved in the pathophysiology of hypertension and ischemic cardiomyopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available